Thanks for signing up for DividendStocks.com! It's the daily newsletter built for dividend and income investors. Before we can begin sending your daily updates, there’s one quick step left. Please confirm your subscription using the link below so our emails reach your inbox. Click Here to Confirm Your Subscription to DividendStocks.com Here’s a small glimpse of what you’ll get access to: Dividend Stock Ideas — Each newsletter features dividend stocks with high yields, sustainable payouts, and strong growth potential. Ex-Dividend Stocks — Want to capture upcoming dividend payouts? Find out which stocks are going ex-dividend this week. Market News and Events — Stay in the loop on the latest developments impacting popular dividend names like AT&T, Exxon Mobil, IBM, Procter & Gamble, and Verizon. Bonus: As a thank-you for confirming, you’ll also receive a free PDF copy of Automatic Income, our popular guide to building wealth through dividend investing. Let’s get your dividend journey started! Discover Top Income-Generating Stocks Here See you in your inbox soon,
The DividendStocks.com Team P.S. Don’t miss out click here to verify your subscription and secure your daily dividend insights and your free investing guide!
Further Reading from MarketBeat A Fresh IPO That Long-Term Investors Shouldn't IgnoreSubmitted by Jordan Chussler. Posted: 1/14/2026. 
Summary - While IPOs are often labeled as high-risk startups, some are worthy of more conservative investors’ attention.
- Aktis Oncology’s IPO—the first biotech IPO of 2026—resulted in a $318 million raise, with the biotech firm receiving $100 million in backing from Big Pharma giant Eli Lilly.
- The company, which now has a market cap of $3.34 billion, develops radiopharmaceuticals and is positioned for long-term success after being listed on the Nasdaq.
For speculative investors, the start of each year is a good time to revisit an initial public offering (IPO) calendar. Companies go public almost every week, and a handful of them can offer considerable short-term upside potential. Of course, IPOs also carry substantial downside risk. Even so, some recently public stocks may deserve a place in buy-and-hold portfolios for investors with lower risk tolerances. While President Trump's official salary is $400,000 per year... his tax returns reveal he's been collecting up to $250,000 PER MONTH from one hidden source. Until recently, most Americans couldn't touch the type of investment that makes up this investment. But thanks to Executive Order 14330, that just changed. If you love investing in disruptive new companies... Discover how to invest in the fund Trump uses to collect this income >> One such company in the healthcare sector that just went public could fit that profile. Last Year's IPO Success Stories Last year is a strong reminder that not all IPOs are ultra-high risk. Some can deliver meaningful returns for long-term investors. AI cloud-computing provider CoreWeave (NASDAQ: CRWV), which went public in March 2025, is up nearly 123% since its IPO. Short-term traders may have benefited from an even larger early move — the stock rose roughly 359% before reaching 30 days on the Nasdaq — but longer-term holders have also enjoyed strong returns. Others, such as Medline (NASDAQ: MDLN), counter the idea that IPOs are all high-risk startups. The medical products and services provider, which debuted publicly in December 2025, was founded in 1966 and already commands a market cap above $55 billion. Similarly, Smithfield Foods (NASDAQ: SFD) — known for its packaged bacon — waited 89 years before going public. Since its January 2025 IPO, the stock is up nearly 5% and has rewarded shareholders with a dividend that currently yields 4.44%, or $1 per share annually, making it an immediate consideration for income investors. After its IPO with shares beginning to trade on Jan. 9, Aktis Oncology (NASDAQ: AKTS), a developer of radiopharmaceuticals, is hoping for a similar outcome in 2026 and beyond. Why Are Radiopharmaceuticals Important? Aktis Oncology specializes in radiopharmaceuticals — a subset of nuclear medicine that uses radioactive drugs for both diagnosis and treatment of conditions such as cancer, heart disease and neurological disorders. Radiopharmaceuticals pair radioactive isotopes with a targeting module that seeks out specific cells (for example, cancer cells) to deliver localized radiation. That focused delivery can limit damage to healthy tissue compared with some conventional radiation therapies. Industry consultant Grand View Research estimated the global nuclear medicine market at nearly $18 billion in 2024 and projects it will approach $35 billion by 2030 — a compound annual growth rate of about 10.16%. Grand View Research also notes that North America accounts for nearly 43% of the global nuclear medicine market, with the United States as the dominant regional player — a favorable dynamic for Boston-based Aktis Oncology. Aktis Oncology's Clinical-Stage Profile Wall Street expects biotech IPO activity to rebound in 2026 after funding cuts under the Trump administration slowed healthcare listings in 2025. Aktis Oncology, which began trading on the Nasdaq on Jan. 9, was the first biotech IPO of 2026 and raised $318 million in the offering. The company now has a market capitalization of about $3.34 billion. According to the company's prospectus, the executive team includes experienced drug developers and commercial leaders who have helped bring 14 currently FDA-approved products to market. In practice, Aktis develops targeted alpha radiopharmaceuticals — a class of precision cancer drugs that use proprietary technology to target solid tumors while minimizing damage to healthy tissue. Aktis Oncology's Eli Lilly Connection Aktis is a clinical-stage, pre-revenue company, but that did not prevent it from attracting a major strategic partner: Eli Lilly (NYSE: LLY) anchored the IPO. According to Reuters, Eli Lilly purchased $100 million of AKTS shares in the offering. This builds on a 2024 partnership between the two companies to develop tumor-targeting radiopharmaceuticals; as part of that deal, Aktis received $60 million in cash and an equity investment from Lilly, with potential milestone payments that could exceed $1 billion. The significance of Eli Lilly's backing is notable. With a market cap around $1.01 trillion, Lilly ranks among the largest pharmaceutical companies, and its net income jumped nearly 109% year over year from 2023 to 2024. That momentum is likely to factor into investor interest when Eli Lilly reports Q4 and full-year 2025 financials on Feb. 5. Between its equity stake and the $100 million purchase of AKTS shares, the maker of Zepbound now has a substantial financial interest in the biotech startup's success.
| 
